Delaney Dennis R lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 4.6% in the 1st quarter, Holdings Channel reports. The fund owned 2,713 shares of the life sciences company’s stock after selling 132 shares during the period. Delaney Dennis R’s holdings in Illumina were worth $843,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in ILMN. Oregon Public Employees Retirement Fund lifted its holdings in shares of Illumina by 66,581.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after acquiring an additional 10,546,495 shares during the last quarter. Norges Bank purchased a new position in Illumina in the 4th quarter worth about $514,627,000. Jennison Associates LLC increased its stake in Illumina by 13.5% in the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares during the period. Massachusetts Financial Services Co. MA increased its position in Illumina by 362.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 433,566 shares of the life sciences company’s stock valued at $130,039,000 after purchasing an additional 339,908 shares during the period. Finally, Vanguard Group Inc increased its position in Illumina by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after purchasing an additional 188,516 shares during the period. Hedge funds and other institutional investors own 90.51% of the company’s stock.
ILMN stock traded down $2.00 during trading on Monday, reaching $312.04. The company had a trading volume of 1,585,187 shares, compared to its average volume of 989,325. The stock has a market capitalization of $46.13 billion, a PE ratio of 54.55, a price-to-earnings-growth ratio of 2.24 and a beta of 1.17. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a twelve month low of $235.74 and a twelve month high of $372.61.
In related news, insider Francis A. Desouza sold 3,000 shares of Illumina stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $316.51, for a total value of $949,530.00. Following the completion of the sale, the insider now directly owns 79,346 shares in the company, valued at approximately $25,113,802.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $321.96, for a total transaction of $1,062,468.00. The disclosure for this sale can be found here. Insiders sold a total of 34,826 shares of company stock valued at $10,665,379 over the last quarter. 0.38% of the stock is owned by company insiders.
A number of research analysts have commented on ILMN shares. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $340.00 to $370.00 in a research report on Thursday, January 3rd. Morgan Stanley cut their target price on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a research report on Monday, January 7th. Leerink Swann raised shares of Illumina to an “outperform” rating and cut their target price for the company from $380.00 to $365.00 in a research report on Wednesday, January 30th. Deutsche Bank downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a research report on Friday, January 25th. Finally, Bank of America restated a “buy” rating and issued a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $353.58.
WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2019/04/29/delaney-dennis-r-has-843000-stake-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.